Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Stablepharma Begins Phase 1 Trial of Fridge-Free Tetanus-Diphtheria Vaccine
Details : SPVX02 is the lead candidate fridge-free tetanus and diphtheria vaccine, currently initiated phase 1 trials in United Kingdom.
Product Name : SPVX02
Product Type : Vaccine
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : EIC Accelerator
Deal Size : $2.6 million
Deal Type : Funding
Stablepharma Secures €2.5M EIC Grant, Recognised Among Europe's Top 71 Innovators
Details : The grant comes as the company will move forward to accelerated the clinical trials for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria vaccine.
Product Name : SPVX02
Product Type : Vaccine
Upfront Cash : Undisclosed
February 19, 2025
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : EIC Accelerator
Deal Size : $2.6 million
Deal Type : Funding